Table 1.

Association analysis between FBI-1 expression and the clinicopathological features of ovarian cancers

		Case assessed	Score (mean ± SE)	p-value
Diagnostic categories	Benign	10	0	0.000a
	Borderline	19	7.83 ± 0.92	0.000a, 0.000b
	Primary cancer	111	12.31 ± 0.37	0.000a
	Metastatic foci	63	13.47 ± 0.46	0.036c
	Malignant ascites	17	14.11 ± 0.87	0.021c
Histological types of ovarian cancer	Serous	43	12.53 ± 1.04	0.070d
	Endometrioid	36	11.82 ± 0.66
	Clear cell	23	12.76 ± 0.53
	Mucinous	9	12.11 ± 1.17
Stage	Stage I	42	11.30 ± 0.67	0.012e
	Stage II-IV	69	13.38 ± 0.42
Grade	Low (grade I)	32	12.22 ± 0.73	0.151f
	High (grade II and III)	79	12.39 ± 0.44
Response to primary chemotherapy	Sensitive	78	12.14 ± 0.45	0.246g
	Resistant	18	13.22 ± 0.92
Survival months	0.53~188.57 (average: 44.7)

^a p Value reflects the comparison of each category vs. benign tumor.

^b p Value reflects the comparison of primary cancer vs. borderline.

^c p Value reflects the comparison of metastatic foci or malignant ascites versus primary cancer.

^d p Value reflects the comparison of clear cell carcinoma versus all the other histological types combined.

^e p Value reflects the comparison of stage I versus stage II-IV.

^f p Value reflects the comparison of low grade versus. high grade.

^g p Value reflects the comparison of chemosensitive versus chemoresistant.